Analysis Report of China Liver Disease Drug Industry 2015
Liver damage can cause a series of diseases. According to the different etiology, liver disease can generally be divided into viral liver disease and non-viral liver disease. Non-viral hepatitis mainly includes alcoholic hepatitis, drug-induced hepatitis or toxin-induced hepatitis, metabolism abnormal hepatitis, hepatic calculus, etc. In 2013, there are total 1,251,900 cases of virus hepatitis reported in China, killing 739 people. Among them, the number of hepatitis A, hepatitis B, hepatitis C and hepatitis E reported were 22,200 cases, 963,000 cases, 203,200 cases, 27,900 cases and 35,600 cases respectively.
Liver disease drug market competition of our country is really fierce. China’s liver disease drug market can be divided into imported drugs and home-made drugs according to the drug producing area. Imported drugs are mainly represented by GlaxoSmithKline and Bristol-Myers Squibb, etc.; the main production enterprises of home-made drugs include Chia Tai Tianqing Pharmaceutical Group, TIPR Pharmaceutical Responsible Company, Fujian Cosunter Pharmaceutical Company, etc. Hepatobiliary system drug has gradually become a variety that costs a large amount of money and it is the third largest one that ranks only second to anti-peptic ulcer and diabetes drug in the digestion metabolism category. In terms of the structure of drug, anti-viral drugs and free regulating drugs account for 30% of liver disease drug, auxiliary drugs account for 25% and Chinese medicine account for 36%.
The sales volume of China liver disease drug in hospital market is increasing. Before 2009, as a result of the continuous introduction of new products, new specifications and new dosage form products, the growth of sales was comparatively large, while its growth began to slow down from 2010. On the one hand, it is due to the hepatitis B vaccination rate has been increased significantly in recent years and the decrease of the expansion speed of hepatitis B patients; on the other hand, the growth of sales has entered a smooth stage. The data issued by China Competition Information shows that, the scale of China liver disease drug market is close to RMB 43 billion in 2013.
China has become the world's top country who pays the most social cost for hepatitis B, liver cirrhosis and hepatoma. The data also shows that there are nearly 100 million Chinese among the 350 million hepatitis B carriers, and China accounts for nearly half of the 700,000 or so viral hepatitis related deaths each year. We have a large number of hepatitis B patients, while the growth of hepatitis C patients and alcoholic liver patients has grown rapidly in recent years. The liver disease diagnosis and treatment in our country has a large mass base. Individualized diagnosis and treatment of liver disease came from abroad. It is developed rapidly in our country in recent years, which puts forward higher requirements for the diagnosis of liver disease and the price ratio of drug curative effect. As the application of new diagnostic techniques and new drugs, the market scale of liver disease diagnosis and treatment industrial chain is still expected to grow steadily.
Liver disease drug market competition of our country is really fierce. China’s liver disease drug market can be divided into imported drugs and home-made drugs according to the drug producing area. Imported drugs are mainly represented by GlaxoSmithKline and Bristol-Myers Squibb, etc.; the main production enterprises of home-made drugs include Chia Tai Tianqing Pharmaceutical Group, TIPR Pharmaceutical Responsible Company, Fujian Cosunter Pharmaceutical Company, etc. Hepatobiliary system drug has gradually become a variety that costs a large amount of money and it is the third largest one that ranks only second to anti-peptic ulcer and diabetes drug in the digestion metabolism category. In terms of the structure of drug, anti-viral drugs and free regulating drugs account for 30% of liver disease drug, auxiliary drugs account for 25% and Chinese medicine account for 36%.
The sales volume of China liver disease drug in hospital market is increasing. Before 2009, as a result of the continuous introduction of new products, new specifications and new dosage form products, the growth of sales was comparatively large, while its growth began to slow down from 2010. On the one hand, it is due to the hepatitis B vaccination rate has been increased significantly in recent years and the decrease of the expansion speed of hepatitis B patients; on the other hand, the growth of sales has entered a smooth stage. The data issued by China Competition Information shows that, the scale of China liver disease drug market is close to RMB 43 billion in 2013.
China has become the world's top country who pays the most social cost for hepatitis B, liver cirrhosis and hepatoma. The data also shows that there are nearly 100 million Chinese among the 350 million hepatitis B carriers, and China accounts for nearly half of the 700,000 or so viral hepatitis related deaths each year. We have a large number of hepatitis B patients, while the growth of hepatitis C patients and alcoholic liver patients has grown rapidly in recent years. The liver disease diagnosis and treatment in our country has a large mass base. Individualized diagnosis and treatment of liver disease came from abroad. It is developed rapidly in our country in recent years, which puts forward higher requirements for the diagnosis of liver disease and the price ratio of drug curative effect. As the application of new diagnostic techniques and new drugs, the market scale of liver disease diagnosis and treatment industrial chain is still expected to grow steadily.
CHAPTER I RELATED OVERVIEW OF LIVER DISEASE DRUG
SECTION I BASIC EXPLANATION OF LIVER DISEASE
I. Classification and Harm of Liver Disease
II. Routes of Transmission
III. Symptoms of Liver Disease
IV. Development Stages of Liver Disease and Prevention and Treatment Measures
SECTION II VIRAL HEPATITIS
I. Hepatitis A Virus (HAV)
II. Hepatitis B Virus (HBV)
III. Hepatitis C Virus (HCV)
IV. Hepatitis D Virus (HDV)
V. Hepatitis E Virus (HEV)
SECTION III ADIPOSIS HEPATICA AND HEPATIC FIBROSIS
I. Adiposis Hepatica
II. Hepatic Fibrosis
SECTION IV THE CLINICAL FEATURES OF HEPATOMA
SECTION V DRUG-INDUCED LIVER INJURY
I. The Clinical Manifestations of Drug-induced Liver Injury
II. The Common Drugs That Are Easy to Cause the Damage of Liver Clinically
III. The Precautionary Measures of Drug-induced Liver Injury
CHAPTER II ANALYSIS OF THE OPERATION SITUATION OF GLOBAL DRUGS FOR THE LIVER DISEASE MARKETS IN 2013
SECTION I ANALYSIS OF MARKET DYNAMICS OF GLOBAL DRUGS FOR THE LIVER DISEASE MARKETS IN 2013
I. Japan Has Exploited New Oral Hepatitis C Vaccine
II. Gilead Has Developed the New Generation of Hepatitis C Drugs
III. The Research of HCV Has Achieved New Breakthrough
SECTION II ANALYSIS OF MARKET DEMAND OF GLOBAL VACCINE FOR THE HEPATITIS IN 2013
I. Overview of Global Vaccine for the Hepatitis Market
II. Analysis of the Sales Status of the Global Vaccine for the Hepatitis
III. Demand Forecast of the Global Vaccine for the Hepatitis Market
SECTION III ANALYSIS OF THE APPLICATION FOR PATENT OF THE GLOBAL HEPATITIS B
I. The Variation Trend of the Application Quantity for Patents
II. Description of Patent Application of Countries or Organizations
III. Description of Patent Application of Main Research and Development Production Agencies on Hepatitis B Vaccine
V. Analysis of patent technology life cycle
CHAPTER III ANALYSIS OF MARKET DEVELOPMENT ENVIRONMENT OF CHINA’S LIVER DISEASE DRUG INDUSTRY IN 2013-2014
SECTION I ANALYSIS OF CHINA’S MACROECONOMIC ENVIRONMENT IN 2014
I. Analysis of China's GDP Growth
II. Analysis of Development Status of Industrial Economy
III. Analysis of Total Investment in Fixed Assets
IV. Total Retail Sales of Consumer Goods
V. Analysis of Income Growth of Urban and Rural Residents
VI. Analysis of Changes in Consumer Prices
VII. Analysis of Development Status of Foreign Trade
SECTION II ANALYSIS OF POLICY ENVIRONMENT FOR CHINA’S LIVER DISEASE DRUG MARKET IN 2013
I. Industrial Competent Authorities
II. Industrial Supervision System
(I) Drug production and business license management
(II) Pharmaceutical Production and Quality Management
(III) Drug Registration Management
(IV) Classification management of prescription and non-prescription drugs
(V) Drug Pricing
(VI) Drug centralized purchasing and distribution
III. Main Laws, Regulations and Policies of the Industry
SECTION III ANALYSIS OF POLICY ENVIRONMENT FOR CHINA’S LIVER DISEASE DRUG MARKET IN 2013
I. Analysis of Population Environment
II. Residents Health Care Spending
III. Analysis of Educational Environment
IV. Analysis of Cultural Environment
V. Analysis of Technical Environment
VI. Analysis of Ecological Environment
SECTION IV THE LEVEL AND FEATURES OF LIVER DISEASE MEDICATION TECHNIQUE
CHAPTER IV HEPATITIS INCIDENCE IN CHINA AND ANALYSIS OF THE STATISTICS OF ITS PREVALENCE IN 2013
SECTION I STATISTICS OF THE VIRAL HEPATITIS INCIDENCE IN CHINA IN 2013
I. Hepatitis A
II. Hepatitis B
III. Hepatitis C
IV. Hepatitis E
SECTION II STATISTICS OF THE VIRAL HEPATITIS DEATH IN CHINA IN 2013
I. Hepatitis A
II. Hepatitis B
III. Hepatitis C
IV. Hepatitis E
SECTION III CHINA AS ALSO THE HIGH INCIDENCE AREA OF HEPATITIS B AND HEPATITIS E
I. The Total Prevalence Rate of Hepatitis C
II. The Total Prevalence Rate of .Hepatitis E
CHAPTER V TYPES OF LIVER MEDICINE
SECTION I ANTIVIRALS
I. Interferon
II. Nucleotide Analogue Antiviral Drug
SECTION II IMMUNOMODULATING DRUG
SECTION III CHINESE PATENT MEDICINE
I. Anti-Hepatic Fibrosis
II. Drugs improving immunity
SECTION IV LIVER PROTECTION DRUGS
I. Vitamin
II. Drugs with Detoxification Function
III. Drugs promoting energy metabolism
IV. Drugs promoting the protein synthesis
CHAPTER VI DEEP RESEARCH OF CHINA LIVER MEDICATION MARKET IN 2013
SECTION I. CHINA LIVER MEDICATION MARKET SCALE
I. China Liver Medication Market Scale
II. Enormous patient group forms the striking liver therapeutic market
SECTION II CHINA LIVER MEDICATION STRUCTURE
SECTION III ANALYSIS OF MEDICATION MARKET
SECTION IV MEDICINE FOR HEPATITIS C AND ANALYSIS OF ITS MARKET DEMAND
SECTION V HEPATOPATHY ADJUVANTS STIMULATE THE HUGE MARKET
CHAPTER VII OBSERVATION ON DYNAMICS OF SEGMENT MARKET OF LIVER DISEASE DRUGS 2013
SECTION I ANALYSIS OF ANTIVIRAL MARKET
I. Analysis of Anti-hepatitis Viral Drugs Market and the Latest Development
II. Market Competition Pattern
III. Overview, Market Analysis and Research Progress of Nucleoside Anti-hepatitis Viruses Drugs
SECTION II MARKET OF IMMUNOMODULATING DRUG
I. Market Analysis of Thymosin
II. Analysis of Market Prospect of Thymopentin
SECTION III CHINESE PATENT MEDICINE
I. Introduction of Traditional Chinese Medicine for Treatment of Hepatitis
II. Oxymatrine-Recommended Traditional Medicine for Anti-hepatitis B Virus
III. Chinese Patent Medicines Are Expected to Fill in the Blanks for the Treatment of Liver Diseases in US
SECTION IV VARIETIES AND MARKET ANALYSIS OF LIVER-PROTECTION MEDICINE
I. Introductions of Liver-protection Medicine
II. Common Liver Drugs Cases
III. Market Competition Tendency of China Liver Drugs
CHAPTER VIII CHINA HEPATITIS B VACCINE MARKET ANALYSIS IN 2013
SECTION I DOMESTIC MARKET PROFILE OF HEPATITIS B VACCINE
SECTION II ANALYSIS OF CHINA HEPATITIS B VACCINE MARKET DEMAND
I. Analysis of China Hepatitis B Epidemic Situation
II. Wholesale Situation of HBV in China
III. China Hepatitis B Vaccine Market Analysis
SECTION III GENETIC ENGINEERED HEPATITIS B VACCINE
I. Hepatitis B Vaccine Expressed by E. Coli System
II. Hepatitis B Vaccine Expressed by Yeast System
III. Hepatitis B Vaccine Expressed by Mammalian Cell System
IV. Prospect of Recombination of HBV
CHAPTER IX COMPARATIVE ANALYSIS OF MAIN ANTI-HEPATITIS DRUGS IN CHINA IN 2012-2013
SECTION I NUCLEOSIDE DRUGS
I. Lamivudine
II. Adefovir Dipivoxil
III. Entecavir
IV. Telbivudine
V. Tenofovir Disoproxil Fumarate
SECTION II INTERFERON
SECTION III ANALYSIS OF OTHER HOT HEPATIC DRUGS MARKETS
I. Yishangfu Capsules
II. Selenium Yeast
III. Caoxian Hepatitis B Capsule
IV. Liver-protection Tablets
V. Inosine injection, inosine oral solution, inosine tablets
CHAPTER X CLINICAL APPLICATION OF LIVERISH RESEARCH RESULTS AND DYNAMIC TRACING OF THE NEWEST RESEARCH RESULTS
SECTION I THE RESEARCH PROCESS OF FATTY LIVER
SECTION II HEPATIC STEM CELLS EXPECTED TO TREAT HEPATIC DISEASE
SECTION III RESEARCHES AND CLINICAL APPLICATIONS OF NEW DRUG OF TREATMENT FOR HEPATIC DISEASES
I. Process of Researching Hepatitis E Vaccine
II. Construction of China's First HCV Infectious Clone
SECTION IV NEW RESEARCH ACHIEVEMENTS OF CMT FOR LIVER DISEASES
I. Introduction of Chinese medicine liver disease treatment methods
II. Application of Certain Medications for the Treatment of Liver in CTM
III. Traditional Chinese medicine has its unique characteristic of curing anti-hepatic fibrosis
CHAPTER XI ANALYSIS OF DYNAMIC AND TREND COMPETITION FOR CHINA’S LIVER DISEASE DRUG MARKET IN 2013
SECTION I GENERAL SITUATION OF COMPETITION IN CHINA’S LIVER DISEASE DRUG IN 2013
I. The Formation of Two Camps of Competition in Liver Disease Drug Market
(I) Imported Drugs and Home-made Drugs
(II)Chinese Patent Medicine and Western Medicine
II. Market Competition Degree
III. The Appearance of Liver Disease Brand in Market
SECTION II ANALYSIS OF DYNAMIC COMPETITION OF CHINA’S LIVER DISEASE DRUG MARKET IN 2013
I. Antiviral Drugs Will Remain the Major Choice of Hepatitis B Drug
II. Anti-virus Medicine
SECTION III ANALYSIS OF COMPETITIVENESS OF LIVER DISEASE DRUG IN ITS SEGMENTAL FIELD IN CHINA IN 2013
I. Liver-protection Medicine Market
II. Traditional Chinese Medicine for Antiviral
III. Analysis of Strength and Weakness of Immunomodulator in Competition
IV. Interferon Market
SECTION IV ANALYSIS OF COMPETITION TREND OF LIVER DISEASE DRUG MARKET IN CHINA 2014-2018
CHAPTER XII SWOT ANALYSIS OF CHINA’S LIVER DISEASE DRUG MARKET IN 2013
SECTION I ADVANTAGE
SECTION II DISADVANTAGE
SECTION III OPPORTUNITY
SECTION IV THREAT
CHAPTER XIII ANALYSIS OF OPERATION CONDITIONS OF TYPICAL DOMESTIC AND FOREIGN DRUGS PRODUCTION Enterprises
SECTION I GLAXOSMITHKLINE
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Analysis of Operation in China
V. Dynamic Analysis of Enterprise Development
SECTION II ROCHE
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Analysis of Development Strategy in China
V. Analysis of Corporate R & D Strength
SECTION III AMERICAN MERCK & CO
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Analysis of Operation in China
V. Dynamic Analysis of Enterprise Development
SECTION IV BEIJING SL PHARMACEUTICAL CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Enterprise Development Planning
SECTION V INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Company Development Strategy
SECTION VI CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Company Development Strategy
SECTION VII FUJIAN COSUNTER PHARMACEUTICAL CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Enterprise Strategic Planning
SECTION VIII TIPR PHARMACEUTICAL RESPONSIBLE CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Company Development Strategy
CHAPTER XIV MARKET DEVELOPING PROSPECTS AND TRENDS ON CHINA’S MEDICATIONS FOR HEPATOPATHY FROM 2015 TO 2020
SECTION I MARKET FORECASTING ON CHINA’S MEDICATIONS FOR HEPATOPATHY FROM 2015 TO 2020
I. Forecast of Development Direction for Treatment on China's Hepatitis B
II. Market Size Forecasting on China’s Medications for Hepatopathy
III. Variation Trend of Profits on China’s Medications Industry for Hepatopathy
SECTION II ANALYSIS OF INVESTMENT RISK OF CHINA’S LIVER DISEASE DRUG INDUSTRY FROM 2015 TO 2020
I. Macroeconomic Fluctuation Risk
II. Risk of New Products Development and Research
III. Products Marketing Risk
IV. Drug Price Adjustment Risk
V. Talent Competition Risks
CHAPTER XV RESEARCH AND ANALYSIS OF CHINA’S LIVER DISEASE DRUG MARKET INVESTMENT FEASIBILITY FROM 2015 TO 2020
SECTION I OVERVIEW OF CHINA’S LIVER DISEASE DRUG MARKET INVESTMENT IN 2013
I. China’s Liver Disease Drug Investment Environment
II. Analysis of Entry Barriers of Liver Disease Drug Industry in China
(I) Administrative entry barriers
(II) Technology barriers
(III) Brand barriers
(IV) Finances barrier
SECTION II ANALYSIS OF INVESTMENT OPPORTUNITY OF LIVER DISEASE DRUG INDUSTRY IN 2014-2018 IN CHINA
I. Research of Investment Hot Spot in Liver Disease Drug Market
II. The Investment Potential of Adjutant Medicine Market of Liver Disease
SECTION III ANALYSIS OF LIVER DISEASE DRUG ENTERPRISE FINANCING CHANNELS AND SELECTION IN 2014-2018
I. Analysis of Liver Disease Drug Enterprise Financing Methods and Channels
II. Planning Enterprise Development Opportunity by Equity Financing
III. Make Use of the Government as a lever to Broaden the Channel of Capital Raising for Enterprises
IV. Moderate debt financing to optimize the enterprise's capital structure
V. Pay Attention to the Investment Trends of Private and Foreign Capital
SECTION IV ADVICE ON STRATEGY OF CHINA LIVER DISEASE DRUG INDUSTRY INVESTMENT IN 2014-2018
SECTION I BASIC EXPLANATION OF LIVER DISEASE
I. Classification and Harm of Liver Disease
II. Routes of Transmission
III. Symptoms of Liver Disease
IV. Development Stages of Liver Disease and Prevention and Treatment Measures
SECTION II VIRAL HEPATITIS
I. Hepatitis A Virus (HAV)
II. Hepatitis B Virus (HBV)
III. Hepatitis C Virus (HCV)
IV. Hepatitis D Virus (HDV)
V. Hepatitis E Virus (HEV)
SECTION III ADIPOSIS HEPATICA AND HEPATIC FIBROSIS
I. Adiposis Hepatica
II. Hepatic Fibrosis
SECTION IV THE CLINICAL FEATURES OF HEPATOMA
SECTION V DRUG-INDUCED LIVER INJURY
I. The Clinical Manifestations of Drug-induced Liver Injury
II. The Common Drugs That Are Easy to Cause the Damage of Liver Clinically
III. The Precautionary Measures of Drug-induced Liver Injury
CHAPTER II ANALYSIS OF THE OPERATION SITUATION OF GLOBAL DRUGS FOR THE LIVER DISEASE MARKETS IN 2013
SECTION I ANALYSIS OF MARKET DYNAMICS OF GLOBAL DRUGS FOR THE LIVER DISEASE MARKETS IN 2013
I. Japan Has Exploited New Oral Hepatitis C Vaccine
II. Gilead Has Developed the New Generation of Hepatitis C Drugs
III. The Research of HCV Has Achieved New Breakthrough
SECTION II ANALYSIS OF MARKET DEMAND OF GLOBAL VACCINE FOR THE HEPATITIS IN 2013
I. Overview of Global Vaccine for the Hepatitis Market
II. Analysis of the Sales Status of the Global Vaccine for the Hepatitis
III. Demand Forecast of the Global Vaccine for the Hepatitis Market
SECTION III ANALYSIS OF THE APPLICATION FOR PATENT OF THE GLOBAL HEPATITIS B
I. The Variation Trend of the Application Quantity for Patents
II. Description of Patent Application of Countries or Organizations
III. Description of Patent Application of Main Research and Development Production Agencies on Hepatitis B Vaccine
V. Analysis of patent technology life cycle
CHAPTER III ANALYSIS OF MARKET DEVELOPMENT ENVIRONMENT OF CHINA’S LIVER DISEASE DRUG INDUSTRY IN 2013-2014
SECTION I ANALYSIS OF CHINA’S MACROECONOMIC ENVIRONMENT IN 2014
I. Analysis of China's GDP Growth
II. Analysis of Development Status of Industrial Economy
III. Analysis of Total Investment in Fixed Assets
IV. Total Retail Sales of Consumer Goods
V. Analysis of Income Growth of Urban and Rural Residents
VI. Analysis of Changes in Consumer Prices
VII. Analysis of Development Status of Foreign Trade
SECTION II ANALYSIS OF POLICY ENVIRONMENT FOR CHINA’S LIVER DISEASE DRUG MARKET IN 2013
I. Industrial Competent Authorities
II. Industrial Supervision System
(I) Drug production and business license management
(II) Pharmaceutical Production and Quality Management
(III) Drug Registration Management
(IV) Classification management of prescription and non-prescription drugs
(V) Drug Pricing
(VI) Drug centralized purchasing and distribution
III. Main Laws, Regulations and Policies of the Industry
SECTION III ANALYSIS OF POLICY ENVIRONMENT FOR CHINA’S LIVER DISEASE DRUG MARKET IN 2013
I. Analysis of Population Environment
II. Residents Health Care Spending
III. Analysis of Educational Environment
IV. Analysis of Cultural Environment
V. Analysis of Technical Environment
VI. Analysis of Ecological Environment
SECTION IV THE LEVEL AND FEATURES OF LIVER DISEASE MEDICATION TECHNIQUE
CHAPTER IV HEPATITIS INCIDENCE IN CHINA AND ANALYSIS OF THE STATISTICS OF ITS PREVALENCE IN 2013
SECTION I STATISTICS OF THE VIRAL HEPATITIS INCIDENCE IN CHINA IN 2013
I. Hepatitis A
II. Hepatitis B
III. Hepatitis C
IV. Hepatitis E
SECTION II STATISTICS OF THE VIRAL HEPATITIS DEATH IN CHINA IN 2013
I. Hepatitis A
II. Hepatitis B
III. Hepatitis C
IV. Hepatitis E
SECTION III CHINA AS ALSO THE HIGH INCIDENCE AREA OF HEPATITIS B AND HEPATITIS E
I. The Total Prevalence Rate of Hepatitis C
II. The Total Prevalence Rate of .Hepatitis E
CHAPTER V TYPES OF LIVER MEDICINE
SECTION I ANTIVIRALS
I. Interferon
II. Nucleotide Analogue Antiviral Drug
SECTION II IMMUNOMODULATING DRUG
SECTION III CHINESE PATENT MEDICINE
I. Anti-Hepatic Fibrosis
II. Drugs improving immunity
SECTION IV LIVER PROTECTION DRUGS
I. Vitamin
II. Drugs with Detoxification Function
III. Drugs promoting energy metabolism
IV. Drugs promoting the protein synthesis
CHAPTER VI DEEP RESEARCH OF CHINA LIVER MEDICATION MARKET IN 2013
SECTION I. CHINA LIVER MEDICATION MARKET SCALE
I. China Liver Medication Market Scale
II. Enormous patient group forms the striking liver therapeutic market
SECTION II CHINA LIVER MEDICATION STRUCTURE
SECTION III ANALYSIS OF MEDICATION MARKET
SECTION IV MEDICINE FOR HEPATITIS C AND ANALYSIS OF ITS MARKET DEMAND
SECTION V HEPATOPATHY ADJUVANTS STIMULATE THE HUGE MARKET
CHAPTER VII OBSERVATION ON DYNAMICS OF SEGMENT MARKET OF LIVER DISEASE DRUGS 2013
SECTION I ANALYSIS OF ANTIVIRAL MARKET
I. Analysis of Anti-hepatitis Viral Drugs Market and the Latest Development
II. Market Competition Pattern
III. Overview, Market Analysis and Research Progress of Nucleoside Anti-hepatitis Viruses Drugs
SECTION II MARKET OF IMMUNOMODULATING DRUG
I. Market Analysis of Thymosin
II. Analysis of Market Prospect of Thymopentin
SECTION III CHINESE PATENT MEDICINE
I. Introduction of Traditional Chinese Medicine for Treatment of Hepatitis
II. Oxymatrine-Recommended Traditional Medicine for Anti-hepatitis B Virus
III. Chinese Patent Medicines Are Expected to Fill in the Blanks for the Treatment of Liver Diseases in US
SECTION IV VARIETIES AND MARKET ANALYSIS OF LIVER-PROTECTION MEDICINE
I. Introductions of Liver-protection Medicine
II. Common Liver Drugs Cases
III. Market Competition Tendency of China Liver Drugs
CHAPTER VIII CHINA HEPATITIS B VACCINE MARKET ANALYSIS IN 2013
SECTION I DOMESTIC MARKET PROFILE OF HEPATITIS B VACCINE
SECTION II ANALYSIS OF CHINA HEPATITIS B VACCINE MARKET DEMAND
I. Analysis of China Hepatitis B Epidemic Situation
II. Wholesale Situation of HBV in China
III. China Hepatitis B Vaccine Market Analysis
SECTION III GENETIC ENGINEERED HEPATITIS B VACCINE
I. Hepatitis B Vaccine Expressed by E. Coli System
II. Hepatitis B Vaccine Expressed by Yeast System
III. Hepatitis B Vaccine Expressed by Mammalian Cell System
IV. Prospect of Recombination of HBV
CHAPTER IX COMPARATIVE ANALYSIS OF MAIN ANTI-HEPATITIS DRUGS IN CHINA IN 2012-2013
SECTION I NUCLEOSIDE DRUGS
I. Lamivudine
II. Adefovir Dipivoxil
III. Entecavir
IV. Telbivudine
V. Tenofovir Disoproxil Fumarate
SECTION II INTERFERON
SECTION III ANALYSIS OF OTHER HOT HEPATIC DRUGS MARKETS
I. Yishangfu Capsules
II. Selenium Yeast
III. Caoxian Hepatitis B Capsule
IV. Liver-protection Tablets
V. Inosine injection, inosine oral solution, inosine tablets
CHAPTER X CLINICAL APPLICATION OF LIVERISH RESEARCH RESULTS AND DYNAMIC TRACING OF THE NEWEST RESEARCH RESULTS
SECTION I THE RESEARCH PROCESS OF FATTY LIVER
SECTION II HEPATIC STEM CELLS EXPECTED TO TREAT HEPATIC DISEASE
SECTION III RESEARCHES AND CLINICAL APPLICATIONS OF NEW DRUG OF TREATMENT FOR HEPATIC DISEASES
I. Process of Researching Hepatitis E Vaccine
II. Construction of China's First HCV Infectious Clone
SECTION IV NEW RESEARCH ACHIEVEMENTS OF CMT FOR LIVER DISEASES
I. Introduction of Chinese medicine liver disease treatment methods
II. Application of Certain Medications for the Treatment of Liver in CTM
III. Traditional Chinese medicine has its unique characteristic of curing anti-hepatic fibrosis
CHAPTER XI ANALYSIS OF DYNAMIC AND TREND COMPETITION FOR CHINA’S LIVER DISEASE DRUG MARKET IN 2013
SECTION I GENERAL SITUATION OF COMPETITION IN CHINA’S LIVER DISEASE DRUG IN 2013
I. The Formation of Two Camps of Competition in Liver Disease Drug Market
(I) Imported Drugs and Home-made Drugs
(II)Chinese Patent Medicine and Western Medicine
II. Market Competition Degree
III. The Appearance of Liver Disease Brand in Market
SECTION II ANALYSIS OF DYNAMIC COMPETITION OF CHINA’S LIVER DISEASE DRUG MARKET IN 2013
I. Antiviral Drugs Will Remain the Major Choice of Hepatitis B Drug
II. Anti-virus Medicine
SECTION III ANALYSIS OF COMPETITIVENESS OF LIVER DISEASE DRUG IN ITS SEGMENTAL FIELD IN CHINA IN 2013
I. Liver-protection Medicine Market
II. Traditional Chinese Medicine for Antiviral
III. Analysis of Strength and Weakness of Immunomodulator in Competition
IV. Interferon Market
SECTION IV ANALYSIS OF COMPETITION TREND OF LIVER DISEASE DRUG MARKET IN CHINA 2014-2018
CHAPTER XII SWOT ANALYSIS OF CHINA’S LIVER DISEASE DRUG MARKET IN 2013
SECTION I ADVANTAGE
SECTION II DISADVANTAGE
SECTION III OPPORTUNITY
SECTION IV THREAT
CHAPTER XIII ANALYSIS OF OPERATION CONDITIONS OF TYPICAL DOMESTIC AND FOREIGN DRUGS PRODUCTION Enterprises
SECTION I GLAXOSMITHKLINE
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Analysis of Operation in China
V. Dynamic Analysis of Enterprise Development
SECTION II ROCHE
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Analysis of Development Strategy in China
V. Analysis of Corporate R & D Strength
SECTION III AMERICAN MERCK & CO
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Analysis of Operation in China
V. Dynamic Analysis of Enterprise Development
SECTION IV BEIJING SL PHARMACEUTICAL CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Enterprise Development Planning
SECTION V INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Company Development Strategy
SECTION VI CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Company Development Strategy
SECTION VII FUJIAN COSUNTER PHARMACEUTICAL CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Enterprise Strategic Planning
SECTION VIII TIPR PHARMACEUTICAL RESPONSIBLE CO., LTD
I. Company Profile
II. Medicines for Hepatitis
III. Analysis of Enterprise Operation
IV. Distribution of Enterprise Marketing Network
V. Analysis of Company Development Strategy
CHAPTER XIV MARKET DEVELOPING PROSPECTS AND TRENDS ON CHINA’S MEDICATIONS FOR HEPATOPATHY FROM 2015 TO 2020
SECTION I MARKET FORECASTING ON CHINA’S MEDICATIONS FOR HEPATOPATHY FROM 2015 TO 2020
I. Forecast of Development Direction for Treatment on China's Hepatitis B
II. Market Size Forecasting on China’s Medications for Hepatopathy
III. Variation Trend of Profits on China’s Medications Industry for Hepatopathy
SECTION II ANALYSIS OF INVESTMENT RISK OF CHINA’S LIVER DISEASE DRUG INDUSTRY FROM 2015 TO 2020
I. Macroeconomic Fluctuation Risk
II. Risk of New Products Development and Research
III. Products Marketing Risk
IV. Drug Price Adjustment Risk
V. Talent Competition Risks
CHAPTER XV RESEARCH AND ANALYSIS OF CHINA’S LIVER DISEASE DRUG MARKET INVESTMENT FEASIBILITY FROM 2015 TO 2020
SECTION I OVERVIEW OF CHINA’S LIVER DISEASE DRUG MARKET INVESTMENT IN 2013
I. China’s Liver Disease Drug Investment Environment
II. Analysis of Entry Barriers of Liver Disease Drug Industry in China
(I) Administrative entry barriers
(II) Technology barriers
(III) Brand barriers
(IV) Finances barrier
SECTION II ANALYSIS OF INVESTMENT OPPORTUNITY OF LIVER DISEASE DRUG INDUSTRY IN 2014-2018 IN CHINA
I. Research of Investment Hot Spot in Liver Disease Drug Market
II. The Investment Potential of Adjutant Medicine Market of Liver Disease
SECTION III ANALYSIS OF LIVER DISEASE DRUG ENTERPRISE FINANCING CHANNELS AND SELECTION IN 2014-2018
I. Analysis of Liver Disease Drug Enterprise Financing Methods and Channels
II. Planning Enterprise Development Opportunity by Equity Financing
III. Make Use of the Government as a lever to Broaden the Channel of Capital Raising for Enterprises
IV. Moderate debt financing to optimize the enterprise's capital structure
V. Pay Attention to the Investment Trends of Private and Foreign Capital
SECTION IV ADVICE ON STRATEGY OF CHINA LIVER DISEASE DRUG INDUSTRY INVESTMENT IN 2014-2018
LIST OF FIGURES
Chart 1 Classification of liver disease
Chart 2 Prevention and treatment measures of liver disease in different stages
Chart 3 Growth trend of sales revenue of the global vaccine for the hepatitis from 2007-2013
Chart 4 Forecast trend of sales revenue of the global vaccine for the hepatitis from 2014-2018
Chart 5 The variation trend of the application quantity for patents of hepatitis B vaccine around the world
Chart 6 The distribution of the patent applications for those top ten countries or organizations in the applications for patents of hepatitis B vaccine
Chart 7 Companies and institutions rank in the top15 in the application number of the patents related to hepatitis B vaccine
Chart 8 Life circle of hepatitis B vaccine patent
Chart 9 China's GDP and growth rate variation during 2009-2014
Chart 10 GDP pattern and corresponding growth rate during 2012-2014
Chart 11 Industrial Growth Rate Trend of 2013-2014 Value Added of Nationwide Scale or Above
Chart 12 China's Fixed-asset Investments of the Whole Society During 2009-2014
Chart 13 China's Total Volume of Social Retail Goods and Growth Rate during 2009-2014
Chart 14 China's Major Retail Sales of Consumer Goods and Growth Rate Statistics in 2014
Chart 15 Per Capita Disposable Incomes of Urban Residents and Growth Rate in 2009-2014
Chart 16 Growth Trend of Per Capita Net Income in China’s Rural Residents from 2008 to 2013
Chart 17 Trend Chart of Monthly Change for Consumption Prices of Chinese Residents in 2013-2014
Chart 18 China's Total Export-import Volume During 2009-2014
Chart 19 Relevant laws and regulations and policy situation statistic of China liver disease medication
Chart 20 Tendency Chart of growth of China's total population from 2008 to 2013
Chart 21 Statistics of Chinese population and composition in 2013
Chart 22 Statistics of China urban and rural residents medical care expenditure in 2005- 2013
Chart 23 Statistics of China's school enrollment at various levels in 2006-2013
Chart 24 Statistics of reports on hepatitis A incidence in China from 2012-2013
Chart 25 Statistics of reports on hepatitis B incidence in China from 2012-2013
Chart 26 Statistics of reports on hepatitis C incidence in China from 2012-2013
Chart 27 Statistics of reports on hepatitis E incidence in China from 2012-2013
Chart 28 Statistics of reports on hepatitis A death cases in China from 2012-2013
Chart 29 Statistics of reports on hepatitis B death cases in China from 2012-2013
Chart 30 Statistics of reports on hepatitis C death cases in China from 2012-2013
Chart 31 Statistics of reports on hepatitis E death cases in China from 2012-2013
Chart 32 Statistics of some domestic products as immunomodulating drug
Chart 33 Rising tendency of China liver medication market scale
Chart 34 The morbidity and mortality of the report on antiviral hepatitis in China during 2012-2013
Chart 35 Distribution of China liver medication structure
Chart 36 Categories of anti-hepatitis viruses drugs
Chart 37 Interferon products and the producers approved by the Chinese government
Chart 38 Comparison of anti-hepatitis drugs
Chart 39 Statistics of Chinese Patent Medicine for treatment of hepatitis
Chart 40 Wholesale situation of recombination of HBV in China in 2010-2013
Chart 41 The situations of liver-protection tablets that have achieved permission of SFDA
Chart 42 Statistics of Report on Brands of Some Liver Disease Drug
Chart 43 GlaxoSmithKline liver disease products table
Chart 44 Statistics of GlaxoSmithKline total assets and operating income 2010-2013
Chart 45 The main products parameter list of Roche's liver disease drugs
Chart 46 Statistics of Roche's total assets and operating income 2011-2013
Chart 47 American Merck & Co total assets and operating income table
Chart 48 Liver disease products table of Beijing SL Pharmaceutical Co., Ltd
Chart 49 Products table of Beijing SL Pharmaceutical Co., Ltd. in 2013
Chart 50 Business structure table of Beijing SL Pharmaceutical Co., Ltd. in 2013
Chart 51 Statistics of the income and profit of Beijing SL Pharmaceutical Co. Ltd. 2011-2014
Chart 52 Districts table of Beijing SL Pharmaceutical Co., Ltd. in 2013
Chart 53 The medication products for hepatopathy of Inner Mongolia Furui Medical Science Co., Ltd
Chart 54 List of products of Inner Mongolia Furui Medical Science Co., Ltd. in 2013
Chart 55 Business structure of Inner Mongolia Furui Medical Science Co., Ltd. in 2013
Chart 56 Statistics of revenue and profit of Inner Mongolia Furui Medical Science Co., Ltd. from 2011 to 2014
Chart 57 List of sub-regions of Inner Mongolia Furui Medical Science Co., Ltd. in 2013
Chart 58 Distribution of the marketing network of Inner Mongolia Furui Medical Science Co., Ltd
Chart 59 List of main products for hepatopathy of Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Chart 60 Statistics in assets and liabilities of Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Chart 61 Statistics in revenue and profits of Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Chart 62 Distribution diagram of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketing Network
Chart 63 Figure of medication products for hepatopathy of Fujian Cosunter Pharmaceutical Co., Ltd
Chart 64 Statistics in total assets and liabilities of Fujian Cosunter Pharmaceutical Co., Ltd. from 2011 to 2013
Chart 65 Business condition of Fujian Cosunter Pharmaceutical Co., Ltd. from 2011 to 2013
Chart 66 The medication products for hepatopathy of TIPR Pharmaceutical Responsible Co., Ltd
Chart 67 Figure Total Assets and Liabilities of TIPR Pharmaceutical Responsible Co., Ltd
Chart 68 Figure Revenues and Profits of TIPR Pharmaceutical Responsible Co., Ltd
Chart 69 Distribution of the marketing network of TIPR Pharmaceutical Responsible Co., Ltd
Chart 70 Trend Chart of market size forecasting on China’s medications for hepatopathy from 2015 to 2020
Chart 71 Variation Trend of profit margins on China's pharmaceutical industry from 2009 to 2013
Chart 72 Classification of Liver Disease Drug Financing Strategies and Channels of Enterprises
Chart 73 Differences between Venture Capital and Private Equity
Chart 74 The operation procedure of venture capital and private equity
Chart 1 Classification of liver disease
Chart 2 Prevention and treatment measures of liver disease in different stages
Chart 3 Growth trend of sales revenue of the global vaccine for the hepatitis from 2007-2013
Chart 4 Forecast trend of sales revenue of the global vaccine for the hepatitis from 2014-2018
Chart 5 The variation trend of the application quantity for patents of hepatitis B vaccine around the world
Chart 6 The distribution of the patent applications for those top ten countries or organizations in the applications for patents of hepatitis B vaccine
Chart 7 Companies and institutions rank in the top15 in the application number of the patents related to hepatitis B vaccine
Chart 8 Life circle of hepatitis B vaccine patent
Chart 9 China's GDP and growth rate variation during 2009-2014
Chart 10 GDP pattern and corresponding growth rate during 2012-2014
Chart 11 Industrial Growth Rate Trend of 2013-2014 Value Added of Nationwide Scale or Above
Chart 12 China's Fixed-asset Investments of the Whole Society During 2009-2014
Chart 13 China's Total Volume of Social Retail Goods and Growth Rate during 2009-2014
Chart 14 China's Major Retail Sales of Consumer Goods and Growth Rate Statistics in 2014
Chart 15 Per Capita Disposable Incomes of Urban Residents and Growth Rate in 2009-2014
Chart 16 Growth Trend of Per Capita Net Income in China’s Rural Residents from 2008 to 2013
Chart 17 Trend Chart of Monthly Change for Consumption Prices of Chinese Residents in 2013-2014
Chart 18 China's Total Export-import Volume During 2009-2014
Chart 19 Relevant laws and regulations and policy situation statistic of China liver disease medication
Chart 20 Tendency Chart of growth of China's total population from 2008 to 2013
Chart 21 Statistics of Chinese population and composition in 2013
Chart 22 Statistics of China urban and rural residents medical care expenditure in 2005- 2013
Chart 23 Statistics of China's school enrollment at various levels in 2006-2013
Chart 24 Statistics of reports on hepatitis A incidence in China from 2012-2013
Chart 25 Statistics of reports on hepatitis B incidence in China from 2012-2013
Chart 26 Statistics of reports on hepatitis C incidence in China from 2012-2013
Chart 27 Statistics of reports on hepatitis E incidence in China from 2012-2013
Chart 28 Statistics of reports on hepatitis A death cases in China from 2012-2013
Chart 29 Statistics of reports on hepatitis B death cases in China from 2012-2013
Chart 30 Statistics of reports on hepatitis C death cases in China from 2012-2013
Chart 31 Statistics of reports on hepatitis E death cases in China from 2012-2013
Chart 32 Statistics of some domestic products as immunomodulating drug
Chart 33 Rising tendency of China liver medication market scale
Chart 34 The morbidity and mortality of the report on antiviral hepatitis in China during 2012-2013
Chart 35 Distribution of China liver medication structure
Chart 36 Categories of anti-hepatitis viruses drugs
Chart 37 Interferon products and the producers approved by the Chinese government
Chart 38 Comparison of anti-hepatitis drugs
Chart 39 Statistics of Chinese Patent Medicine for treatment of hepatitis
Chart 40 Wholesale situation of recombination of HBV in China in 2010-2013
Chart 41 The situations of liver-protection tablets that have achieved permission of SFDA
Chart 42 Statistics of Report on Brands of Some Liver Disease Drug
Chart 43 GlaxoSmithKline liver disease products table
Chart 44 Statistics of GlaxoSmithKline total assets and operating income 2010-2013
Chart 45 The main products parameter list of Roche's liver disease drugs
Chart 46 Statistics of Roche's total assets and operating income 2011-2013
Chart 47 American Merck & Co total assets and operating income table
Chart 48 Liver disease products table of Beijing SL Pharmaceutical Co., Ltd
Chart 49 Products table of Beijing SL Pharmaceutical Co., Ltd. in 2013
Chart 50 Business structure table of Beijing SL Pharmaceutical Co., Ltd. in 2013
Chart 51 Statistics of the income and profit of Beijing SL Pharmaceutical Co. Ltd. 2011-2014
Chart 52 Districts table of Beijing SL Pharmaceutical Co., Ltd. in 2013
Chart 53 The medication products for hepatopathy of Inner Mongolia Furui Medical Science Co., Ltd
Chart 54 List of products of Inner Mongolia Furui Medical Science Co., Ltd. in 2013
Chart 55 Business structure of Inner Mongolia Furui Medical Science Co., Ltd. in 2013
Chart 56 Statistics of revenue and profit of Inner Mongolia Furui Medical Science Co., Ltd. from 2011 to 2014
Chart 57 List of sub-regions of Inner Mongolia Furui Medical Science Co., Ltd. in 2013
Chart 58 Distribution of the marketing network of Inner Mongolia Furui Medical Science Co., Ltd
Chart 59 List of main products for hepatopathy of Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Chart 60 Statistics in assets and liabilities of Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Chart 61 Statistics in revenue and profits of Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Chart 62 Distribution diagram of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketing Network
Chart 63 Figure of medication products for hepatopathy of Fujian Cosunter Pharmaceutical Co., Ltd
Chart 64 Statistics in total assets and liabilities of Fujian Cosunter Pharmaceutical Co., Ltd. from 2011 to 2013
Chart 65 Business condition of Fujian Cosunter Pharmaceutical Co., Ltd. from 2011 to 2013
Chart 66 The medication products for hepatopathy of TIPR Pharmaceutical Responsible Co., Ltd
Chart 67 Figure Total Assets and Liabilities of TIPR Pharmaceutical Responsible Co., Ltd
Chart 68 Figure Revenues and Profits of TIPR Pharmaceutical Responsible Co., Ltd
Chart 69 Distribution of the marketing network of TIPR Pharmaceutical Responsible Co., Ltd
Chart 70 Trend Chart of market size forecasting on China’s medications for hepatopathy from 2015 to 2020
Chart 71 Variation Trend of profit margins on China's pharmaceutical industry from 2009 to 2013
Chart 72 Classification of Liver Disease Drug Financing Strategies and Channels of Enterprises
Chart 73 Differences between Venture Capital and Private Equity
Chart 74 The operation procedure of venture capital and private equity
